2024
A Pilot Study to Test the Feasibility of a Randomized Controlled Trial of E-cigarettes as Harm Reduction Tools Among People Who Smoke and Previously Failed to Quit With Pharmacotherapy
Smith T, Ferreira A, Wahlquist A, Cummings K, Rojewski A, McClure E, Toll B, Carpenter M. A Pilot Study to Test the Feasibility of a Randomized Controlled Trial of E-cigarettes as Harm Reduction Tools Among People Who Smoke and Previously Failed to Quit With Pharmacotherapy. Nicotine & Tobacco Research 2024, ntae212. PMID: 39233579, DOI: 10.1093/ntr/ntae212.Peer-Reviewed Original ResearchRandomized controlled trialsE-cigarette groupE-cigarettesNRT groupPilot studyPoint prevalence abstinenceNicotine replacement therapyHarm reduction interventionsHarm reduction toolCombination nicotine replacement therapyTraditional pharmacotherapyTrial of e-cigarettesMean cigarettesReduction interventionsPrevalence abstinencePowered trialsControlled trialsEffect sizeNon-whiteElectronic diaryCigarette smokersReplacement therapyParticipantsStandard pharmacotherapyDaily diaries
2007
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain
Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 2007, 33: 173-179. PMID: 17587504, PMCID: PMC2488403, DOI: 10.1016/j.addbeh.2007.05.012.Peer-Reviewed Original ResearchConceptsPost-cessation weight gainWeight-concerned smokersPoint prevalence abstinenceWeight gainAbstinent participantsSustained-release bupropion hydrochlorideHigher smoking cessation ratesWeight suppressant effectsOpen-label studyPercentage of patientsSmoking cessation ratesLess weight gainDays of treatmentNaltrexone augmentationAdverse eventsCombination pharmacotherapyPrimary outcomeCessation ratesTreatment regimenCigarette smokersClinical trialsContinuous abstinenceLabel studyPsychosocial interventionsBupropion